Robert E. Conway, Director at Nivalis Therapeutics, Inc. (NVLS), bought 15,000 shares at $2.28 ($34K) on 2017-05-08, disclosed to the SEC on 2017-05-11.
Open-market purchase of $34k NVLS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| ALPN | BUY | 2021-09-23 | $98K | — | Filing → |
| ABIO | BUY | 2021-05-13 | $32K | — | Filing → |
| ABIO | BUY | 2021-05-06 | $32K | — | Filing → |